Skip to main content
editorial
. 2015 Jun 14;21(22):6794–6808. doi: 10.3748/wjg.v21.i22.6794

Table 3.

Data derived from the main published studies that have evaluated apparent diffusion coefficient values before and after trans-arterial treatments of primary and metastatic liver tumors

Study n b values (s/mm2) ADC before treatment(× 10-3 mm2/s) ADC after treatment(× 10-3 mm2/s) Histotype Treatment
Kamel et al[86] 38 0, 500 1.51 1.70 HCC TACE
Sahin et al[87] 74 0, 50, 400, 800 1.10 1.27 HCC TACE
Kamel et al[88] 24 0, 50, 750 1.86 2.13 HCC TACE
Chen et al[89] 20 0, 500 1.56 2.09 HCC TACE
Yuan et al[90] 41 0, 500 2.22 1.42 HCC TACE
Deng et al[98] 6 0, 500 1.30 2.23 HCC TARE
Kamel et al[99] 13 0, 500 1.65 1.95 HCC TARE
Rhee et al[100] 20 0, 500 1.64 1.82 HCC TARE
Mannelli et al[102] 36 0, 50, 500 1.64 1.92 HCC TACE
Kubota et al[103] 25 0, 500 1.271 1.3571/1.2222 HCC TACE
Liapi et al[120] 26 0, 500 1.51 1.79 Metastases (PanNET) TACE
Li et al[121] 26 0, 750 1.31 1.59 Metastases (PanNET) TACE
1

No disease relapse;

2

Disease relapse. ADC values are presented as means. n: Number of patients; ADC: Apparent diffusion coefficient; HCC: Hepatocellular carcinoma; PanNET: Pancreatic neuroendocrine tumor; TACE: Trans-arterial chemoembolization; TARE: Trans-arterial radioembolization.